Full Press Release Details
Innovating to Transform the Lives of Patients and Their Families Markella EPIDIOLEX patient diagnosed with Dravet syndrome January 2025
Transforming Lives. Redefining Possibilities. Caution Concerning
Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including
the ability of the Company's portfolio to drive long-term shareholder value; expectations with respect to indication expansion opportunities; 2024 total, neuroscience and oncology revenue guidance and the Company's expectations related
thereto; the Company's ability to drive significant cash flow generation; the Company's commercial expectations, including with respect to revenue diversification and its expectations for significant growth; the Company's
expectations with respect to the commercial potential of its products and product candidates, including the blockbuster potential for Epidiolex, the peak potential of zanidatamab, growth opportunities for Rylaze, Epidiolex/Epidyolex, Xywav and
Ziihera and Zepzelca's potential approval as a first line therapy, and the potential regulatory paths related thereto; the value and growth potential of its products; the Company's net product sales and goals for net product sales from
new and acquired products; the Company's views and expectations relating to its patent portfolio, including with respect to expected patent protection; planned or anticipated clinical trial events, including with respect to initiations,
enrollment and data read-outs, and the anticipated timing thereof, and planned or anticipated regulatory submissions and filings and other regulatory matters, including potential approvals, including the timing thereof; and other statements that are
not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of
events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and
revenue from Xywav, Rylaze, Zepzelca, Epidiolex / Epidyolex, Ziihera and other key marketed products; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and
regulatory activities with respect to the Company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk
that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and
the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients such as those experienced, and expected to be experienced, by the Company; regulatory
initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon its obtaining, maintaining and defending intellectual
property protection for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those
governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these
transactions and successfully integrating acquired product candidates, products and businesses; the Company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the
Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's
ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and
objectives; the completion of financial closing procedures, final audit adjustments and other developments that may arise that would cause the Company's expectations with respect to the Company's 2024 revenue guidance to differ, perhaps
materially, from the financial results that will be reflected in the Company's audited consolidated financial statements for the fiscal year ended December 31, 2024; and other risks and uncertainties affecting the Company, including those
described from time to time under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended
December 31, 2023 as supplemented by the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and its future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also
affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this presentation are made only as of the date hereof or as of the dates
indicated in the forward-looking statements, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual
results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. January 2025 2
Our Purpose is to innovate to transform the lives of patients and their
families. Who We Are We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully. Jennie Caroline Xywav patient living with IH Rylaze
patient diagnosed with ALL / LBL ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma; IH = idiopathic hypersomnia. January 2025 3
Positioned to Drive Long-term Shareholder Value PIPELINE Zanidatamab and
Zepzelca indication expansion COMMERCIAL opportunities; additional Growth and diversified pipeline programs under revenues expected to generate development Operational significant cash flow excellence and a disciplined, strategic approach to capital
allocation CORPORATE DEVELOPMENT Financial strength to transact and well-positioned to be partner of choice January 2025 4
Growing and Diversified Commercial Portfolio 1 2018 Revenue 2021 Revenue
2024 Guidance $1.9 billion $3.1 billion $4.0 - $4.1 billion 74% 41% 11% 2 Launched / of revenues driven of revenues driven of revenues driven by Xyrem in 2018 by Xyrem in 2021 by Xyrem and AG Acquired royalties in 3Q24 Xyrem & Products AG
royalties Oncology + Epidiolex + Other Revenues Xyrem Revenue + AG Royalty Revenue Xywav Revenue 1 AG royalties = high-sodium oxybate authorized generic royalty revenues. The company expects that for the year ended December 31, 2024, reported total,
neuroscience and oncology revenues will meet the guidance range provided January 2025 5 2 on November 6, 2024. Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2024, and actual results may differ;
Chart based on revenue as reported in 3Q24.
Strategic Transactions Driving Growth and Expanding Capabilities
WELL-POSITIONED FOR ZEPZELCA GW ACQUISITION ZANIDATAMAB CORPORATE DEVELOPMENT Rapidly Accretive Transaction Transformational Transaction Broad Oncology Development Transaction FINANCIAL STRENGTH $2.6B in cash, cash equivalents and 3
investments Rapidly established as treatment Durable and long-lived asset Significant regulatory progress 4 of choice in 2L SCLC in Epidiolex with extensive development ~$1.0B cash from operations program ongoing 1 2
5 >$1.1B in revenue since launch >$2.7 billion in revenue since $885M undrawn revolving credit facility in mid-2020 acquisition mid-2021 Path to approval in 1L GEA with PARTNER OF CHOICE anticipated sBLA
submission Positive Phase 3 results from Epidiolex poised to reach in 2025 Demonstrated global commercial IMforte trial; Plan to submit sNDA blockbuster status in 2025 footprint and capabilities for 1L ES-SCLC in 1H25
$2B+ peak sales potential Expanded operational footprint and A leader in neuroscience in-house R&D capabilities Rapidly growing oncology business In-house development expertise Track record of maximizing
2019 2021 2022 asset potential 1L/2L = first- and second-line; ES = extensive stage; GEA = gastroesophageal adenocarcinoma; R&D = research and development; sBLA = supplemental biologics license application; SCLC = small cell lung cancer; sNDA =
supplemental new drug application. 1 2 3 4 5 January 2025 6 Net product sales from launch in July 2020 to September 30, 2024; Net product sales from May 2021 to September 30, 2024; As of September 30, 2024; For the nine months ended September 30,
2024; As of December 31, 2024.
Track Record of Successfully Growing and Diversifying Commercial
Portfolio Expect to meet 2024 total, neuroscience and $4.0B- $4.1B 1 $3.8B oncology revenue guidance $3.7B $3.1B 20 Consecutive Years $2.4B $2.2B $1.9B YoY Revenue Growth 2005 - 2024G 13.5% Total Revenue CAGR 2 2018 - 2024G midpoint 2018
2019 2020 2021 2022 2023 2024G Oncology 3 Neuroscience 1 2024G = 2024 financial guidance as provided by Jazz Pharmaceuticals plc on November 6, 2024; CAGR = compound annual growth ra te; YoY = year-over-year. The company expects that, for the year
ended December 31, 2024, reported total, neuroscience 2 and oncology revenues will meet the guidance range provided on November 6, 2024. Jazz Pharmaceuticals plc has not finalized its financial results for the year ended December 31, 2024, and
actual results may differ; Based on mid-point of guidance January 2025 7 3 provided by Jazz Pharmaceuticals plc on November 6, 2024; Neuroscience revenues include high-sodium oxybate authorized generic royalties.
Pipeline Focused Investments in Promising R&D Portfolio January 2025
Key Pipeline Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY
NEAR-TERM CATALYSTS Key Clinical Programs 2L BTC (pivotal) Ziihera approved in 2L BTC in 4Q24 Phase 3 1L GEA (pivotal) Phase 3 top-line PFS readout estimated 2Q25 Phase 3 1L BTC Phase 3 confirmatory trial in 1L BTC ongoing Zanidatamab Phase 3
BC in patients who have progressed on previous T-DXd treatment Phase 3 EmpowHER-BC-303 trial now enrolling I-SPY2 Trial: neoadjuvant treatment of locally advanced BC Phase 2 pan-tumor trial in HER2+ solid tumors Phase 2 DiscovHER-Pan-206 trial
initiated 1L ES-SCLC combo with Tecentriq Positive OS and PFS data: expect sNDA filing in 1H25 Phase 4 2L SCLC observational trial Zepzelca Phase 3 2L SCLC confirmatory trial RAF & RAS mutant tumors JZP815 Solid tumors JZP898 Japan (LGS/TSC/DS)
Epidyolex 1L/2L = first- and second-line; BC = breast cancer; BTC = biliary tract cancer; DS = Dravet syndrome; ES = extensive-stage; GEA = gastroesophageal adenocarcinoma; HER2+ = human epidermal growth factor receptor 2 positive; LGS =
Lennox-Gastaut January 2025 9 syndrome; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental new drug application; T-DXd = trastuzumab deruxtecan; TSC = tuberous sclerosis complex.
Zanidatamab Has the Potential to Transform HER2-Targeted Therapies
Zanidatamab is a highly active, differentiated HER2-targeted bispecific mAb with compelling and durable survival data Best-in-Class $2B+ Novel and Compelling Profile Commercial Differentiated Clinical Data in Addresses Opportunity MOA Multiple Unmet
Need Indications HER2 = human epidermal growth factor receptor 2; mAb = monoclonal antibody; MOA = mechanism of action. January 2025 10
Rapidly Advancing Zanidatamab Development Program 2024 2025 2026 and
Beyond BTC BTC BTC Expect to complete 1L confirmatory Ziihera approved in 2L BTC in 4Q24 Potential EU approval as early trial as 2Q25 Initiated 1L confirmatory trial GEA GEA 2L BTC MAA validated by EMA
Potential 1L approval and launch HERIZON-GEA-01 top-line results GEA Expanded market strategy estimated 2Q25 Enrollment on track for Phase 3 Expect to submit sBLA in 1L BC HERIZON-GEA-01 trial
Potential further development in Ongoing execution of BC neoadjuvant / adjuvant GEA population EmpowHER-BC-303 trial Phase 3 EmpowHER-BC-303 trial initiated Pan Tumor Pan Tumor Ongoing execution of Phase 2
DiscovHER-Pan-206 trial initiated DiscovHER-Pan-206 trial Goal: become the HER2-targeted therapy of choice 1L/2L= first- and second-line; BC = breast cancer; BTC = biliary tract cancer; EMA = European Medicines Agency; EU = European Union; GEA =
gastroesophageal adenocarcinoma; HER2 = human epidermal growth factor receptor 2; MAA = marketing January 2025 11 authorization application; sBLA = supplemental biologics license application.
Zepzelca: Positive Top-Line Results from 1L ES-SCLC Phase 3 Trial 1
SCLC U.S. Patients IMforte Phase 3 Trial: 30K Demonstrated statistically significant and clinically meaningful 27K improvement in OS and PFS primary endpoints for 1L ES-SCLC 9K Potential to delay disease progression and extend
survival for patients 8K Plan to submit sNDA for 1L ES-SCLC indication in 1H25 17K Significant unmet need: 21K 2 Expected median OS for 1L ES-SCLC patients is ~13 months 19K In the U.S., there are ~30,000 1L SCLC patients,
with ~27,000 currently 1 treated in 1L and ~17,000 treated in 2L 1 ~70% of 1L patients have extensive stage SCLC Diagnosed 1L Treatment 2L Treatment LS SCLC ES SCLC 2L+ SCLC 1 1L / 2L = first- and second-line; ES = extensive stage; LS =
limited stage; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental New Drug Application. Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts
https://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019; American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessed April 12, 2 2019; Kantar Health Treatment
Architecture SCLC July 2018; Jazz primary market research May 2019; Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung January 2025 12 cancer: 3-year
overall survival update from CASPIAN. ESMO Open. 2022 Apr; 7(2):100408.
Key Commercial Products Highly Differentiated Therapies Poised for
Growth January 2025 13
Highly Differentiated Medicines for Patients with Serious Diseases 1
Top-line growth driven by diversified businesses spanning Sleep, Epilepsy and Oncology, each annualizing >$1B Oncology Neuroscience Potential to be the #1 treatment Standard of care in #1 branded treatment #1 branded treatment therapy of choice
in in 2L ES-SCLC; pediatric ALL/LBL for epilepsy for narcolepsy and only multiple HER2+ expansion opportunity patients with approved IH therapy tumors in 1L ES-SCLC asparaginase HSR reaction Diverse product mix + strong cash flow generation 1L / 2L
= first- and second-line; ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma; ES-SCLC = extensive-stage small cell lung cancer; HER2+ = human epidermal growth factor receptor 2 +; HSR = hypersensitivity; 1 January 2025 14 IH =
idiopathic hypersomnia. Based on 3Q24 revenues.
Ziihera: Unique MOA Drives Compelling Clinical Profile and Patient
Outcomes Compelling and Favorable Combination data Unique dual-targeting durable responses tolerability profile supports ability to HER2 bispecific help drive improved contributes to combine with other antibody provides patient outcomes in improved
patient agents in multiple differentiated treatment HER2+ patients quality of life HER2+ indications HER2 = human epidermal growth factor receptor 2; MOA = mechanism of action. January 2025 15
BTC Launch: Building Momentum for Multiple Indications Ziihera Clinical
Data 51.6% 14.9m 2.5% Overall Median Duration Discontinuation 1 1 1 Response Rate of Response Rate Mark Ziihera patient living with Biliary Tract Cancer Establish Ziihera as the standard Build momentum for Ziihera's potential as a Launch of
care for 2L HER2+ BTC transformative next-generation HER2-targeting agent objectives 1 2L = second line; ASCO = American Society of Clinical Oncology; BTC = biliary tract cancer; HER2 = human epidermal growth factor receptor 2; M = month. Data as
presented by Pant et al. at ASCO 2024. January 2025 16
BTC Launch Driven by Proven Jazz Oncology Team and Infrastructure
Proven team with deep oncology experience, including extensive expertise in the HER2 therapy Right Team, space will help drive additional adoption and uptake Right Capabilities Infrastructure in place for a successful Ziihera launch
Significant overlap in existing call universe covering key customers and accounts Key Customer Focus Leverage Jazz's established presence across sales, marketing, medical and access Access, distribution, reimbursement,
and patient support services ensure customers can readily Robust Access and Patient Support order Ziihera, help patients navigate reimbursement approvals, and provide patient support Services through dedicated Jazz Resources and the JazzCares suite
of services BTC = biliary tract cancer; HER2 = human epidermal growth factor receptor 2. January 2025 17
Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential
Significant regulatory progress: Ziihera now approved in the U.S. for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC3+) BTC Other HER2-Expressing EMA validated MAA; potential approval as early
as 2Q25 Cancers Breast Cancer Broad potential beyond BTC, GEA, and BC in multiple HER2-expressing indications based on 1 6 Expanded opportunity across lines of therapy : compelling clinical activity from early trials : Post T-DXd (Ph3
EmpowHER trial) Colorectal Gastroesophageal Early lines of therapy (neoadjuvant) NSCLC Novel combinations Ovarian Adenocarcinoma Biliary Tract Cancer Endometrial Initiated Ph3 EmpowHER trial 2H24: Path